Last $2.34 USD
Change Today -0.04 / -1.68%
Volume 1.6M
CTIC On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/14 - $4.22
52 Week Low
11/7/14 - $2.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the treatment of ovarian cancer; in phase II clinical trials for the treatment of malignant brain cancer; and is in phase II clinical trials for the treatment of head and neck cancer. Additionally, it is developing Brostallicin, which is in phase II clinical trials for the treatment of triple-negative breast cancer. The company has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat in North, Central, and South America, or the licensed territory; and a development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA to develop and commercialize Pacritinib worldwide. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

111 Employees
Last Reported Date: 03/4/14
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $553.5K
Co-Founder, Chief Compliance Officer, Interim...
Total Annual Compensation: $551.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $585.0K
Compensation as of Fiscal Year 2013.

cti biopharma corp (CTIC) Key Developments

CTI Biopharma Corp. Approves Amendment to the Amended and Restated Articles of Incorporation

CTI BioPharma Corp. shareholders approved an amendment to the Company's Amended and Restated Articles of Incorporation, as amended. Such changes contained in the Articles Amendment apply to the rights of all holders of the Company's capital stock. The Articles Amendment, which became effective upon its filing with the Secretary of State of the State of Washington on February 27, 2015, increases the total number of authorized shares from 215,333,333 to 315,333,333 and increases the total number of authorized shares of common stock from 215,000,000 to 315,000,000.

CTI BioPharma Corp. Names Alan K. Burnett as Therapeutic Area Lead, Myeloid Diseases

CTI BioPharma Corp. announced the appointment of Alan K. Burnett to serve as the strategic leader for myeloid development. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University. In his new role, Burnett will be responsible for creating and implementing the strategic development program for CTI BioPharma's compounds in myeloid malignancies. The major focus will be on supplementing CTI BioPharma's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia. Burnett will also help to identify promising earlier stage targets and therapeutics for potential development collaborations.

CTI Biopharma Corp. Announces an Analysis of Kinase Inhibition by Pacritinib

CTI BioPharma Corp. announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 clinical development, demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. One of the findings observed in clinical trials to date is the lack of myelosuppression seen with other treatments. Pacritinib's potent inhibition of FLT3, c-fms, IRAK1 and c-kit, all critical targets in hematologic malignancies, highlights its potential therapeutic utility in other indications, such as AML, MDS, CMML and CLL. The in vitro profiling of pacritinib across a panel of kinases showed the inhibition of all members of the JAK/FLT pathways, with the exception of JAK1. The JAK/FLT pathways are frequently dysregulated in many types of cancers. Additionally, pacritinib was found to inhibit the kinases c-fms and IRAK1. Disruption in the c-fms and IRAK1 pathways have been indicated to be involved in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL). CTI believes the clinical efficacy and reduced myelosuppression seen in Phase 2 trials of pacritinib in patients with myelofibrosis is also likely attributable to this unique kinase inhibition profile.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $2.34 USD -0.04

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curis Inc $3.08 USD -0.07
Cytokinetics Inc $7.71 USD -0.25
Evotec AG €3.83 EUR -0.003
Exelixis Inc $2.93 USD 0.00
Progenics Pharmaceuticals Inc $6.51 USD -0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 18.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at